Literature DB >> 10741399

IL-12 gene-deficient C57BL/6 mice are susceptible to Leishmania donovani but have diminished hepatic immunopathology.

A R Satoskar1, S Rodig, S R Telford, A A Satoskar, S K Ghosh, F von Lichtenberg, J R David.   

Abstract

To determine the in vivo role of IL-12 in the development of protective immunity in visceral leishmaniasis caused by Leishmania donovani, we examined the course of L. donovani infection in IL-12-deficient C57BL/6 (IL-12-/-) mice. IL-12-/- mice displayed significantly higher parasite burdens in their livers and spleens than wild-type C57BL/6 mice throughout the course of infection. Despite high parasite burdens, the onset of hepatosplenomegaly was significantly delayed in L. donovani-infected IL-12-/-. Moreover, livers and spleens from IL-12-/- mice displayed significantly less inflammation and poorly formed granulomatous lesions than those from IL-12+/+ mice throughout the course of infection. Antigen-stimulated splenocytes from IL-12-/- mice produced significantly less IFN-gamma but more IL-4 than IL-12+/+ mice. These findings indicate that although endogenous IL-12 is critical for the development of protective immunity to L. donovani, it is also responsible for inducing the significant immunopathology associated with visceral leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10741399     DOI: 10.1002/1521-4141(200003)30:3<834::AID-IMMU834>3.0.CO;2-9

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  27 in total

Review 1.  Clinical and experimental advances in treatment of visceral leishmaniasis.

Authors:  H W Murray
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

Review 2.  Concepts of immunostimulation to increase antiparasitic drug action.

Authors:  K Noel Masihi
Journal:  Parasitol Res       Date:  2003-01-08       Impact factor: 2.289

3.  Endogenous interleukin-12 is not required for resolution of Chlamydophila abortus (Chlamydia psittaci serotype 1) infection in mice.

Authors:  L Del Río; A J Buendía; J Sánchez; M C Gallego; M R Caro; N Ortega; J Seva; F J Pallarés; F Cuello; J Salinas
Journal:  Infect Immun       Date:  2001-08       Impact factor: 3.441

4.  Antagonizing deactivating cytokines to enhance host defense and chemotherapy in experimental visceral leishmaniasis.

Authors:  Henry W Murray; Kathleen C Flanders; Debra D Donaldson; Joseph P Sypek; Philip J Gotwals; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2005-07       Impact factor: 3.441

5.  Responses to Leishmania donovani in mice deficient in interleukin-12 (IL-12), IL-12/IL-23, or IL-18.

Authors:  Henry W Murray; Christine W Tsai; Jianguo Liu; Xiaojing Ma
Journal:  Infect Immun       Date:  2006-07       Impact factor: 3.441

6.  Temporal regulation of interleukin-12p70 (IL-12p70) and IL-12-related cytokines in splenic dendritic cell subsets during Leishmania donovani infection.

Authors:  Asher Maroof; Paul M Kaye
Journal:  Infect Immun       Date:  2007-11-12       Impact factor: 3.441

7.  Respiratory tract infection with Mycoplasma pneumoniae in interleukin-12 knockout mice results in improved bacterial clearance and reduced pulmonary inflammation.

Authors:  C M Salvatore; M Fonseca-Aten; K Katz-Gaynor; A M Gomez; A Mejias; C Somers; S Chavez-Bueno; G H McCracken; R D Hardy
Journal:  Infect Immun       Date:  2006-10-30       Impact factor: 3.441

Review 8.  The power of combinatorial immunology: IL-12 and IL-12-related dimeric cytokines in infectious diseases.

Authors:  Christoph Hölscher
Journal:  Med Microbiol Immunol       Date:  2003-06-27       Impact factor: 3.402

9.  Regulatory actions of Toll-like receptor 2 (TLR2) and TLR4 in Leishmania donovani infection in the liver.

Authors:  Henry W Murray; Yunhua Zhang; Yan Zhang; Vanitha S Raman; Steven G Reed; Xiaojing Ma
Journal:  Infect Immun       Date:  2013-04-15       Impact factor: 3.441

Review 10.  Cytokines and their STATs in cutaneous and visceral leishmaniasis.

Authors:  Hannah E Cummings; Rashmi Tuladhar; Abhay R Satoskar
Journal:  J Biomed Biotechnol       Date:  2010-03-15
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.